Risk assessment of the impact on human health of resistant Campylobacter jejuni from fluoroquinolone use in beef cattle

被引:41
作者
Anderson, SA [1 ]
Woo, RWY [1 ]
Crawford, LM [1 ]
机构
[1] Georgetown Univ, Ctr Food & Nutr Policy, Washington, DC 20007 USA
关键词
risk assessment; Campylobacter; fluoroquinolone resistance;
D O I
10.1016/S0956-7135(00)00014-1
中图分类号
TS2 [食品工业];
学科分类号
0832 ;
摘要
Use of antimicrobials in livestock is controversial and may lead to the emergence of resistant organisms that could be transmitted to humans through the food supply. Our quantitative risk assessment employs Monte Carlo methodology to analyze the potential public health risk from Campylobacter jejuni and fluoroquinolone (FQ)-resistant C. jejuni because of fresh beef and ground beef consumption. The quantitative study begins with beef products in the retail display case. Data from a variety of sources have been assembled into the model as predictors of the prevalence and quantity of C. jejuni in specific types of beef. Consumer behaviors handling, cooking and consumption - are modeled in our study to predict exposure. The consequences of exposure in some individuals are infection, illness, hospitalization, or even death. We estimated that approximately 16,000 individuals in the US might be infected by C. jejuni derived from both ground beef and fresh beef sources. Furthermore, we predicted the probability of adverse consequences arising from both C. jejuni and FQ-resistant C. jejuni Results from our quantitative risk assessment model are lower when compared to similar public health outcomes for beef products estimated by the Centers for Disease Control (CDC) and the US Department of Agriculture's Economic Research Service (USDA-ERS). However, incorporation of uncertainty and variability in estimates from our model and the CDC and USDA-ERS suggest that the disparity among the estimates is small. (C) 2000 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:13 / 25
页数:13
相关论文
共 44 条
  • [1] DEVELOPMENT OF RESISTANCE TO QUINOLONES IN 5 PATIENTS WITH CAMPYLOBACTERIOSIS TREATED WITH NORFLOXACIN OR CIPROFLOXACIN
    ADLERMOSCA, H
    LUTHYHOTTENSTEIN, J
    LUCCHINI, GM
    BURNENS, A
    ALTWEGG, M
    [J]. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1991, 10 (11) : 953 - 956
  • [2] Campylobacter jejuni
    Altekruse, SF
    Swerdlow, DL
    Stern, NJ
    [J]. VETERINARY CLINICS OF NORTH AMERICA-FOOD ANIMAL PRACTICE, 1998, 14 (01) : 31 - +
  • [3] FOODBORNE DISEASE OUTBREAKS IN THE UNITED-STATES, 1973-1987 - PATHOGENS, VEHICLES, AND TRENDS
    BEAN, NH
    GRIFFIN, PM
    [J]. JOURNAL OF FOOD PROTECTION, 1990, 53 (09) : 804 - 817
  • [4] EXPERIMENTAL CAMPYLOBACTER-JEJUNI INFECTION IN HUMANS
    BLACK, RE
    LEVINE, MM
    CLEMENTS, ML
    HUGHES, TP
    BLASER, MJ
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1988, 157 (03) : 472 - 479
  • [5] CAMPYLOBACTER-JEJUNI SURVIVAL IN CHICKEN MEAT AS A FUNCTION OF TEMPERATURE
    BLANKENSHIP, LC
    CRAVEN, SE
    [J]. APPLIED AND ENVIRONMENTAL MICROBIOLOGY, 1982, 44 (01) : 88 - 92
  • [6] Quantitative risk assessment for Escherichia coli O157:H7 in ground beef hamburgers
    Cassin, MH
    Lammerding, AM
    Todd, ECD
    Ross, W
    McColl, RS
    [J]. INTERNATIONAL JOURNAL OF FOOD MICROBIOLOGY, 1998, 41 (01) : 21 - 44
  • [7] *CAST, 1994, R122 CAST
  • [8] Centers forDisease Control Prevention., 1988, Morbidity and Mortality Weekly Report, V37, P1
  • [9] THE USE OF ANTIMICROBIAL DRUGS IN NAGPUR, INDIA - A WINDOW ON MEDICAL-CARE IN A DEVELOPING-COUNTRY
    DUA, V
    KUNIN, CM
    WHITE, LV
    [J]. SOCIAL SCIENCE & MEDICINE, 1994, 38 (05) : 717 - 724
  • [10] THE INFECTIVITY OF CRYPTOSPORIDIUM-PARVUM IN HEALTHY-VOLUNTEERS
    DUPONT, HL
    CHAPPELL, CL
    STERLING, CR
    OKHUYSEN, PC
    ROSE, JB
    JAKUBOWSKI, W
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (13) : 855 - 859